Form 4: Health Catalyst Director John Kane Receives Significant RSU Grant

Health Catalyst, Inc. Director John A. Kane was granted 36,231 restricted stock units, increasing his beneficial ownership to 170,719 shares, as disclosed in a recent SEC Form 4 filing.

Summary

• John A. Kane, a Director of Health Catalyst, Inc. (HCAT), was granted 36,231 restricted stock units (RSUs) on July 9, 2025.
• These RSUs were awarded pursuant to the Issuer's 2019 Stock Option and Incentive Plan, with each RSU representing a contingent right to receive one share of Health Catalyst's common stock.
• The RSUs are scheduled to fully vest on the earlier of the one-year anniversary of the grant date or the date of the next Annual Meeting of the Issuer's Stockholders.
• Following this transaction, John A. Kane's beneficial ownership of Health Catalyst common stock totals 170,719 shares.
• The reported beneficial ownership includes 3,493 shares that were not previously reported due to an inadvertent administrative error, which has now been corrected.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is generally positive for aligning interests. The minor administrative error is a slight negative but corrected, leading to a neutral-to-slightly positive sentiment.

Positives

• The grant of 36,231 restricted stock units to a director aligns management incentives with shareholder interests, encouraging long-term value creation.
• The vesting schedule, tied to either a one-year anniversary or the next Annual Meeting, provides a clear timeline for equity realization and continued commitment from the director.

Negatives

• An inadvertent administrative error led to 3,493 shares not being previously reported, which, while corrected, indicates a minor reporting oversight.

Future Outlook

The RSUs granted to Director John A. Kane are set to fully vest on the earlier of the one-year anniversary of the grant date (July 9, 2026) or the date of the next Annual Meeting of Stockholders, indicating a future equity realization event.

Industry Context

This filing is a routine disclosure of insider equity transactions, common across all publicly traded companies. It reflects standard compensation practices for directors, aligning their interests with long-term company performance in the healthcare technology sector.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to directors is a common practice in the technology and healthcare technology sectors, similar to compensation structures at companies like Cerner (now Oracle Health), Epic Systems, or Allscripts (now Veradigm).
• The vesting schedule, typically over one to four years or tied to specific events like annual meetings, is standard for director equity awards, aiming to retain talent and incentivize long-term value creation.
• The administrative error in reporting a small number of shares is a minor issue, not uncommon in large organizations, and its correction demonstrates compliance with reporting requirements.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with long-term shareholder value creation, potentially leading to more focused governance.
• Management/Employees: Reinforces the company's compensation structure for key personnel, potentially boosting morale and retention.

Next Steps

• The RSUs granted to John A. Kane will vest on the earlier of July 9, 2026, or the date of the next Annual Meeting of Health Catalyst's Stockholders.

Key Dates

Recommendation

Keywords

Health Catalyst, HCAT, John A. Kane, Director, Restricted Stock Units, RSU, SEC Form 4, Insider Trading, Equity Grant, Stock Option Plan, Beneficial Ownership